Alto has reported positive outcomes from the interim analysis of its Phase IIb trial of oral ALTO-300, as an adjunctive ...

GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.

AnaptysBio’s trial saw 69% of its rheumatoid arthritis patients treated with rosnilimab achieve low disease activity by week ...

Moleculin Biotech has received approval in Ukraine to begin enrolment in its trial of annamycin with cytarabine for acute ...

Patients who received a single injection of Lumevoq displayed sustained clinical recovery in a rare condition that can lead ...

Trump's tariffs will not only impact sponsors, but higher costs will ripple down the clinical trial supply chain in the US.

Palvella Therapeutics is set to expand Phase III SELVA trial to include subjects aged three to five years old.

The trial will see healthy volunteers infected with dengue to test the impact of AbViro’s monoclonal antibody therapy.

Rallybio has dosed the first subject in a trial of a potential treament for foetal and neonatal alloimmune thrombocytopaenia (FNAIT).

BMS has reported that the Phase II TRANSCEND FL trial assessing Breyanzi, met its primary endpoint in the marginal zone ...

Historical epidemiological analysis has demonstrated an association between urbanisation and growing cancer burden across the ...

Cyclo Therapeutics’ Trappsol Cyclo was able to induce clinical improvement in seven out of eight children with Neimann-Pick ...